Medicare Enrolled
Dr. Azmat Iqbal, MD
Hematology & Oncology · Sunnyside, NY
Practice pattern: Clinical Cardiology
— Primarily office-based clinical cardiology
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Iqbal from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Iqbal?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Iqbal
Dr. Azmat Iqbal is a hematology & oncology specialist in Sunnyside, NY, with 20 years of NPI registration. Based on federal Medicare data, Dr. Iqbal performed 2,439 Medicare services across 1,075 unique beneficiaries.
Between the years covered by Open Payments, Dr. Iqbal received a total of $10,568 from 33 pharmaceutical and/or device companies across 233 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Iqbal is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice
▲ Top 29% volume in NY
$10,568 industry payments
Medicare Practice Summary
Medicare Utilization ↗2,439
Medicare services
Top 29% in NY for hematology & oncology
1,075
Unique beneficiaries
$74
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~122 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
459 | $72 | $150 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
420 | $81 | $174 |
| Home visit, established patient, low complexity A physician visits an existing patient at their residence to provide care involving a low level of medical decision making. The visit lasts at least 30 minutes. |
169 | $69 | $157 |
| Home visit, established patient, moderate complexity A home visit for an established patient involving moderate medical decision making. The visit requires at least 40 minutes of time if time is used to determine the level of service. |
155 | $116 | $198 |
| Nursing facility visit, low complexity A daily follow-up visit for an existing patient in a nursing facility involving straightforward medical decision making. The visit requires at least 15 minutes of time if time is used to determine the level of care. |
145 | $68 | $152 |
| SARS-CoV-2 immunoassay test A laboratory test using immunoassay techniques to detect the presence of severe acute respiratory syndrome coronavirus. |
139 | $35 | $100 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
129 | $8 | $67 |
| Nursing facility visit, established patient, straightforward A follow-up visit by a healthcare provider at a nursing facility for an established patient. The visit involves straightforward medical decision making and lasts at least 10 minutes. |
114 | $35 | $104 |
| Office visit, established patient (10-19 min) An office visit for an existing patient lasting 10 to 19 minutes. The visit involves medical evaluation and management of the patient's condition. |
112 | $50 | $104 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
101 | $155 | $250 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
88 | $115 | $199 |
| New patient office visit (30-44 min) An initial office visit for a new patient lasting between 30 and 44 minutes. This code is used when the total time spent on the date of the encounter falls within this range. |
85 | $106 | $225 |
| Home visit, established patient, straightforward decision making A home visit for an established patient involving straightforward medical decision making. The visit lasts at least 15 minutes when time is used to determine the level of service. |
80 | $40 | $152 |
| Advance care planning consultation, first 30 min A session focused on discussing and documenting future healthcare preferences and goals. This service covers the initial 30 minutes of the planning discussion. |
43 | $68 | $151 |
| Initial nursing facility care, high complexity An initial visit by a healthcare provider to a patient in a nursing facility involving a high level of medical decision making, lasting at least 45 minutes. |
34 | $164 | $250 |
| Nursing facility discharge management, more than 30 minutes This service involves care coordination and management activities performed by a healthcare professional to prepare a patient for discharge from a nursing facility. It requires more than 30 minutes of time spent on these activities. |
31 | $120 | $250 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
30 | $12 | $60 |
| Nursing facility visit, moderate complexity A follow-up visit by a healthcare provider at a nursing facility for an established patient. The visit involves moderate medical decision making and takes at least 30 minutes. |
26 | $93 | $200 |
| Home visit, new patient, moderate complexity A home visit for a new patient involving moderate medical decision making, lasting at least 60 minutes. |
25 | $128 | $262 |
| COVID-19 amplified DNA/RNA probe detection A laboratory test that uses amplified DNA or RNA probes to detect the presence of severe acute respiratory syndrome coronavirus 2 (COVID-19) antigen. |
22 | $50 | $125 |
| Influenza virus detection test A laboratory test that uses an immunoassay technique to detect the presence of the influenza virus through direct visual observation. |
19 | $16 | $110 |
| Urinalysis, manual A manual laboratory examination of a urine sample to check for various substances and cells. |
13 | $3 | $15 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
Industry Payment Transparency
Open Payments through 2024 ↗$10,568
Total received (2018-2024)
Avg $1,510/year across 7 years
Top 25% in NY for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
33
Companies
233
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$5,807 (54.9%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$4,365 (41.3%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$396 (3.7%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$462
2023
$516
2022
$1,143
2021
$1,430
2020
$826
2019
$5,407
2018
$782
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
AstraZeneca Pharmaceuticals LP
$148
PFIZER INC.
$121
PUMA BIOTECHNOLOGY, INC.
$45
Gilead Sciences, Inc.
$30
Novartis Pharmaceuticals Corporation
$28
Celgene Corporation
$27
Exact Sciences Corporation
$21
TAIHO ONCOLOGY, INC.
$21
Incyte Corporation
$20
Top 3 companies account for 67.9% of 2024 payments
All-time payments by company (2018-2024) ›
Incyte Corporation
$4,711
AstraZeneca Pharmaceuticals LP
$1,171
PFIZER INC.
$788
Lilly USA, LLC
$541
Novartis Pharmaceuticals Corporation
$503
Janssen Biotech, Inc.
$437
E.R. Squibb & Sons, L.L.C.
$357
Athenex Pharmaceutical Division, LLC
$278
GlaxoSmithKline, LLC.
$253
Dova Pharmaceuticals
$196
Gilead Sciences, Inc.
$168
ARRAY BIOPHARMA INC
$107
Seagen Inc.
$99
Abbott Laboratories
$99
Philips Electronics North America Corporation
$90
TAIHO ONCOLOGY, INC.
$89
Lexicon Pharmaceuticals, Inc.
$69
Celgene Corporation
$67
PUMA BIOTECHNOLOGY, INC.
$61
Merck Sharp & Dohme LLC
$61
UCB, Inc.
$50
Merck Sharp & Dohme Corporation
$47
Taiho Oncology, Inc.
$47
Daiichi Sankyo Inc.
$46
Global Blood Therapeutics, Inc.
$42
Puma Biotechnology, Inc.
$42
Amgen Inc.
$25
ACADIA Pharmaceuticals Inc
$24
G1 Therapeutics, Inc.
$23
GENZYME CORPORATION
$22
Exact Sciences Corporation
$21
Qiagen, LLC
$16
Verastem, Inc.
$15
Top 3 companies account for 63.1% of all-time payments
Associated products mentioned in payments ›
(6575) Coronary Undivided · AIRSUPRA · BOSULIF · BRAFTOVI · Briviact · CHANTIX · COSELA · CYRAMZA · Cologuard Collection Kit · Confirm Rx · Copiktra · DARZALEX · Doptelet · ERLEADA · FARXIGA · FASENRA · FASLODEX · IBRANCE · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · Inrebic · JAKAFI · JEVTANA · KANJINTI · KEYTRUDA · KISQALI · LOKELMA · LONSURF · LYNPARZA · MEKINIST · MONJUVI · NERLYNX · NUCALA · NUPLAZID · OPDIVO · ORGOVYX · OXBRYTA · Oraxol · PROMACTA · QUANTIFERON-TB GOLD PLUS · REBLOZYL · SCEMBLIX · SUTENT · SYMBICORT · TAGRISSO · TASIGNA · TRELEGY ELLIPTA · TUKYSA · Trodelvy · VERZENIO · VOTRIENT · XALKORI · XTANDI · Xermelo
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (55%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Hematology & oncology specialists within 10 mi
741
Per 100K population
31.8
County median income
$84,961
Nearest hospital
ELMHURST HOSPITAL CENTER
2.2 mi
2.2 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Iqbal is a clinical cardiology specialist, with above-average Medicare volume (top 29% in NY), with low-engagement industry engagement, with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Iqbal experienced with hospital follow-up visit, moderate complexity?
Based on Medicare claims data, Dr. Iqbal performed 459 hospital follow-up visit, moderate complexity services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Iqbal receive payments from pharmaceutical companies?
Yes. Dr. Iqbal received a total of $10,568 from 33 companies across 233 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Iqbal's costs compare to other hematology & oncology specialists in Sunnyside?
Dr. Iqbal's average Medicare payment per service is $74. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Iqbal) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Sunnyside
Browse hematology & oncology specialists in Sunnyside ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in NY
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in NY
Which NY hematology & oncology specialists receive the most from drug and device companies.
By company
Incyte Corporation Payments to Doctors
See all physicians who received payments from Incyte Corporation.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
PFIZER INC. Payments to Doctors
See all physicians who received payments from PFIZER INC.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology